[52] BAJAJ PS，VEENSTRA DL，GOERTZ HP，et erlotinib for first-line treatment of advanced non-small cell lung cancer：a budget impact analysis[J] .J Med Econ，2014，17（8）：538-546.

[53] EMOHARE O，LEDONIO CG，HILL BW，et al.Cost savings analysis of intra-wound vancomycin powder in posterior spinal surgery[J] .Spine J，2014，14（11）：2710-2715.

[54] MONTOUCHET C，RUFF L，BALU S.Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective[J] .J Med Econ，2013，16（7）：907-916.

[55] ZHANG JJ，NELLESEN D，LUDLAM WH，et impact of pasireotide LAR for the treatment of acromegaly，a rare endocrine disorder[J] .J Med Econ，2016，19（4）：374-385.

[56] IVANOVA JI，KELKAR S，KING S，et impact model of a 5-grass sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis[J] .J Med Econ，2015，18（11）：909-918.

[57] SAUNDERS R，LIAN J，KAROLICKI B，et al.The costeffectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes：evaluation of the FullSTEP trial[J] .J Med Econ，2014，17（12）：827-836.

[58] MERCHANT S，NOE LL，HOWE A，et impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain[J] .Clin Ther，2013，35（5）：659-672.

[59] CHIAO E，MEYER K.Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis[J] .Curr Med Res Opin，2009，25（6）：1445-1454.

[60] DANESE MD，REYES C，NORTHRIDGE K，et impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced，nonresectable or metastatic pancreatic cancer[J] .Clin Ther，2008，30（4）：775-784.

[61] LEE LJ，SMOLEN LJ，KLEIN TM，et impact analysis of insulin therapies and associated delivery systems[J] .Am J Health Syst Pharm，2012，69（11）：958-965.

[62] PERK S，WIELAGE RC，CAMPBELL NL，et budget impact of increased use of mirabegron，a novel treatment for overactive bladder[J] .J Manag Care Spec Pharm，2016，22（9）：1072-1086.

[63] JENSEN IS，LODISE TP，FAN W，et al.Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics：a US hospital budget impact analysis[J] .Clin Drug Investig，2016，112（2）：157-168.

[64] JENSEN IS，WU E，FAN W，et al.Use of oritavancin in moderate-to-severe absssi patients requiring iv antibiotics：a US payer budget impact analysis[J] .J Manag Care Spec Pharm，2016，22（6）：752.

[65] CARLTON R，MALLICK R，CAMPBELL C，et the expected costs and budget impact of interventional therapies for the treatment of chronic venous disease[J] .Am Health Drug Benefits，2015，8（7）：366-374.

[66] PENN MS，YENIKOMSHIAN MA，CUMMINGS AK，et al.The economic impact of implementing a multiple inflammatory biomarker-based approach to identify，treat，and reduce cardiovascular risk[J] .J Med Econ，2015，18（7）：483-491.

[67] MEHTA DA，OLADAPO AO，EPSTEIN JD，et al.A budget impact model of hemophilia bypassing agent prophylaxis relative to recombinant factorⅦa on-demand[J] .J Manag Care Spec Pharm，2016，22（2）：149.

[68] LANE W，WEATHERALL J，GUNDGAARD J，et degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US：a budget impact analysis with rebate tables[J] .J Med Econ，2018，21（2）：144-151.

[69] KEUFFEL E，MCCULLOUGH PA，TODORAN TM，et al.The effect of major adverse renal cardiovascular event（MARCE）incidence，procedure volume and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty[J] .J Med Econ，2017，21（4）：356-364.

[70] VEENSTRA DL，GUZAUSKAS GF，VILLA KF，et al.The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant[J] .J Med Econ，2017，20（5）：453-463.

[71] ASCHE CV，KIM M，FELDMAN SR，et impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs[J] .J Med Econ，2017，20（9）：1000-1006.

[72] LAU BD，PINTO BL，THIEMANN DR，et impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake[J] .Clin Ther，2011，33（11）：1792-1796.

[73] CARLSON JJ，WONG WB，VEENSTRA DL，et impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer[J] .J Med Econ，2011，14（2）：159-166.

[74] WOODWARD TC，BROWN R，SACCO P，et impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients[J] .J Med Econ，2010，13（3）：492-499.

[75] AUGUSTO M，GREENE M，TOUYA M，et impact analysis of long-acting injectable aripiprazole oncemonthly 400 mg in bipolarⅠdisorder in the USA[J] .J Comp Eff Res，2018，7（7）：627-636.

文章来源：《中国药物经济学》 网址: http://www.zgywjjx.cn/qikandaodu/2020/1023/578.html